CHIHYUNG CHIANG

Dr. CHIHYUNG CHIANG


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Polymers
Verified
Journal Article
Open access
PDF file
HCHsuan-Yu Chen
Hsuan-Yu Chen
TLTzu-Chieh Lin
Tzu-Chieh Lin
CCCHIHYUNG CHIANG
CHIHYUNG CHIANG
SWShiuan-Li Wey
Shiuan-Li Wey
Feng-Huei LinFeng-Huei Lin
Feng-Huei Lin
MHMing-Hsiao Hu
Ming-Hsiao Hu
The application of antifibrotic materials can alleviate epidural fibrosis by restricting excessive fibroblast proliferation and mitigating scar tissue formation. Here, a biodegradable carboxymethyl cellulose (CMC)-Bletilla striata polysaccharide (BSP)-resveratrol (RES) sponge was fabricated to inhibit scar tissue formation post laminectomy surgery. Fibroblasts NIH/3T3, myoblasts C2C12, neural cells PC-12, and Schwann cells RSC96 were used to evaluate the in vitro cytocompatibility. Laminectomies on 10 Sprague–Dawley rats with/without the application of the CMC-BSP-RES sponge were performed. The severity of adhesion between the dura mater and formed scar tissue was qualitatively scored. All cell lines exhibited good viability with no significant difference in cytotoxicity when cultured with variable extractions of the CMC-BSP-RES sponge. S100a4 and P4hb expressions were downregulated in NIH/3T3 cultured in the CMC-BSP-RES sponge, implying that this sponge potentially inhibits fibroblast activity. No post-operative shrinkage or dura mater expansion along the surgical site was detected. The peel-off tests revealed that the tenacity of adhesion de-creased. Histopathological examinations verified that the average number of fibroblasts in the CMC-BSP-RES group considerably decreased. The CMC-BSP-RES sponge is a biocompatible and effective material for alleviating post-operative epidural fibrosis and mitigating fibroblast expression following laminectomy.

4 July 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
CCCHIHYUNG CHIANG
CHIHYUNG CHIANG
PLPo-Wei Lee
Po-Wei Lee
CWChang-Chin Wu
Chang-Chin Wu
A biphasic osteochondral construct has been developed to repair focal chondral and osteochondral lesions. This study aimed to evaluate the safety and preliminary clinical feasibility of using the biphasic osteochondral construct in treating patients having mild-to-moderate-stage knee osteoarthritis. This single-center, prospective, open-label, single-arm feasibility trial compared 2-year knee functional outcome (KOOS and IKDC scores), pain VAS score, and radiological assessment of repaired cartilage (MOCART score) after treatment versus the corresponding preoperative scores. All enrolled patients had a clinical history of primary knee osteoarthritis (OA), Kellgren Lawrence grade 1–3 without valgus or varus deformity greater than 5 degrees. Five men and three women completed the two-year follow-up, with a mean age of 53.9 ± 9.3 years (range 34–63 years). The average lesion size was 4.5 ± 2.9 cm2 (range 2–9 cm2). The patients received one to three biphasic osteochondral constructs. No major adverse effects or complications were reported postoperatively. The mean KOOS subscale values, VAS scores, and IKDC scores were all improved significantly at six months post operation and were maintained for two years. The changes in MOCART scores of the regenerated cartilage were parallel to the changes observed in KOOS values. Our findings provide preliminary evidence of the safety and clinical feasibility of using biphasic osteochondral constructs to treat focal chondral and osteochondral lesions in patients with mild- or moderate-stage osteoarthritis, and support the rationale for larger controlled trials.